Abbott will commercialize HDC’s diagnostics, and Quest Diagnostics will leverage the firm’s biomarkers for a new test.



Health Discovery (HDC) inked two separate agreements related to its prostate cancer diagnostic program. It has given Abbott the right to commercialize its gene-based tests for clinically significant prostate cancer.


Abbott acquired coexclusive clinical laboratory rights and exclusive in vitro diagnostic rights for HDC’s tissue-based and urine-based prostate cancer test.


Additionally, HDC licensed rights to Quest Diagnostics for the development of a urine-based test for clinically significant prostate cancer. Under the terms of this agreement, HDC will receive payments, royalties, and additional undisclosed financial considerations.



To comment on this story, go to BLOGbiotech.








This site uses Akismet to reduce spam. Learn how your comment data is processed.